IRCCS Azienda Ospedaliero-Universitaria di Bologna
Age
18–38
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 and ≤ 38 years at the time of cryopreservation
Patient diagnosed with breast cancer or lymphoma, who underwent ovarian biopsy and cryopreservation of ovarian tissue prior to the initiation of gonadotoxic treatment
Gonadotoxic therapy completed at least 6 months prior
Written informed consent obtained for participation in the study and for the processing of personal, sensitive, and genetic data
You may not be if
Patients with a history of gonadotoxic treatments prior to ovarian tissue cryopreservation
Patients undergoing hormonal therapy that suppresses ovarian function (e.g., GnRH analogs)
Presence of other conditions potentially responsible for premature ovarian insufficiency \[e.g., BRCA1 and BRCA2 mutations, Li-Fraumeni syndrome, Bloom syndrome, Fanconi anemia, Fragile X syndrome, Cowden syndrome, Lynch syndrome (Hereditary Non-Polyposis Colorectal Cancer - HNPCC), Ataxia-Telangiectasia\]
Family history of premature ovarian insufficiency
Clareo Health | Genetic Markers of Susceptibility to Chemotherapy-induced Ovarian Damage in Cancer Patients Undergoing Ovarian Biopsy for Cryopreservation.
